Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) causes side effects in most people who take it for weight loss, and the majority are gastrointestinal. Nausea is the most commonly reported, affecting roughly half of participants in clinical trials; it tends to peak in the first few weeks at each dose level, then settle. Understanding what's typical, what passes quickly, and what needs prompt medical attention lets you approach treatment with clear eyes. As a prescription-only medicine, Mounjaro is only available following clinical assessment by a registered prescriber, who will discuss your individual risk profile before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest starting point is that most people on tirzepatide for weight loss notice some digestive disruption, particularly in the first few weeks. Nausea is the headline, but the fuller picture from the SURMOUNT-1 trial includes vomiting, diarrhoea, constipation, acid reflux, burping, and stomach discomfort at varying frequencies. Fatigue and headache appear less often, as do dizziness and injection-site reactions (redness, mild swelling, itching at the injection point).
The pattern matters as much as the list. Symptoms tend to spike after each dose step upward, which is why the prescribing schedule starts at the lowest strength and moves gradually. Many people report that nausea is noticeable on injection day and the day after, then fades. Eating smaller portions, avoiding very fatty meals, and staying well hydrated all reduce the burden for most people. The full breakdown of Mounjaro's side effects for weight loss covers practical management tips in more detail.
One practical note on routine: keeping your pen in the fridge door and injecting on the same day each week helps turn it into a habit rather than a decision, which in turn makes it easier to track any pattern in how you feel afterwards.
Yes. Several effects are infrequent but serious, and knowing them in advance is part of taking the medicine safely.
Acute pancreatitis is the most significant. In January 2026 the MHRA issued a Drug Safety Update emphasising that GLP-1 medicines, including tirzepatide, carry a known risk of acute pancreatitis. The warning signs are severe, persistent stomach pain that may spread toward your back, sometimes accompanied by vomiting. This is not ordinary nausea. If you experience it, stop eating, seek urgent medical care, and tell the clinician you are taking tirzepatide. You can also report it via the Yellow Card scheme.
Gallbladder problems are also associated with rapid weight loss generally and with GLP-1 medicines specifically. Sudden pain in the upper right abdomen, particularly after eating, warrants a call to your GP or 111.
Allergic reactions are rare but possible: facial swelling, breathing difficulty, or a widespread rash need emergency attention.
Severe dehydration can develop if vomiting or diarrhoea is prolonged. Signs include dizziness on standing, very dark urine, and inability to keep fluids down. Call 111 or see a GP. Full safety context, including less common effects, is covered on the Mounjaro safety overview.
For most people, the worst of the GI symptoms belong to the early weeks. Once the body has adapted to a given dose, nausea, loose stools and fatigue commonly reduce or disappear before the next scheduled dose increase. Some people find they return briefly at each new strength, then settle again.
A smaller proportion of people continue to experience nausea throughout treatment. In those cases, prescribers may slow the titration pace or discuss whether the medicine remains the right fit. The long-term side effects of tirzepatide are an active area of monitoring given the medicine's Black Triangle (▼) status with the MHRA, which means ongoing post-authorisation safety studies are in place.
Muscle loss is occasionally raised as a concern. Rapid weight loss from any cause can reduce lean mass alongside fat; adequate protein and resistance exercise are the standard advice from prescribers and dietitians for people on treatment. This is worth discussing during your consultation, not something to self-manage in isolation.
The tirzepatide-specific side-effect data drawn from the SURMOUNT programme gives more granular figures for those who want them.
Before a prescription is issued, a GPhC-registered Independent Prescriber reviews your health information personally. That review considers your full medical history, current medicines, and any factors that raise your individual risk — pancreatitis history and certain gastrointestinal conditions, for instance, affect whether Mounjaro is appropriate at all.
Side effects are not an afterthought in that conversation. The prescriber looks at your profile and can advise on which symptoms are worth monitoring closely in your case. After treatment starts, our clinical team is available seven days a week if something changes or a symptom concerns you — not just at the next repeat review. You can also read accounts from people who have been through the titration process on the Mounjaro reviews and side effects page, which keeps the picture honest rather than selective.
If you want to understand your options across all available treatments before committing, the weight loss treatment overview sets out the full picture. When you are ready, our prescribers discuss suitability and side effects as part of every free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.